Theravance fins medical solutions
I added Theravance Inc (THRX) to the Barchart Van Meerten New High portfolio. They are focused on the discovery, development and commercialization of small molecule medicines for unmet medical needs across a number of therapeutic areas including respiratory disease, bacterial infections, overactive bladder and gastrointestinal disorders.
The stock hit 19 new highs in the last 20 sessions with a 51.29% price increase last month alone. Barchart has a 96% buy signal. The stock trades around 19.41 far above its 50 day moving average of 15.24. The 14 day Relative Strength Index is 80.57% and rising.
The stock doesn't have a wide following but it is positive with the CAPS members on Motley Fool voting 64 to 29 that the stock will beat the market and the All Stars agree 25 to 11. Fool notes that the last 9 Wall Street columnists' articles have been positive.
The brokerage firms have 5 buy recommendations published based on a consensus of sales increases of 13.00% this year and 35.30% next year. The earnings per share are expected to increase 12.60% this year, 6.50% next year and maintain a 34.70% annual EPS growth rate for at least 5 years.
The major 3 criteria are met:
1 - Recent and positive price momentum
2- A positive investor sentiment
3 - Wall Street buy report based on double digit projections of increases in sales and earnings
Jim Van Meerten is an advisor to Marketocracy Capital Management who uses his model portfolios not only to manage their mutual funds but also their clients Separately Managed Accounts. You can read his blogs about those model portfolios and investing here and on Barchart Portfolio Blogs. Please leave a comment below or email mailto:JimVanMeerten@gmail.com
Disclosure: Jim Van Meerten through Marketocracy Capital Management has an interest in the stocks mentioned in this blog.